NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物相似藥的全球市場 - 產品、應用、規定

Global Biosimilars Market - Products, Applications and Regulations

出版商 Industry Experts 商品編碼 983086
出版日期 內容資訊 英文 356 Pages, 223 Pages
訂單完成後即時交付
價格
生物相似藥的全球市場 - 產品、應用、規定 Global Biosimilars Market - Products, Applications and Regulations
出版日期: 2021年01月11日內容資訊: 英文 356 Pages, 223 Pages
簡介

全球生物相似藥市場,腫瘤學具優勢,從2020年的54億美元(38.6%的佔有率),到2026年達到248億美元,2020年∼2026年預計以29%的年複合成長率成長。

本報告提供全球生物相似藥市場相關調查分析,世界/各地區市場分析及預測,主要企業等相關的系統性資訊。

目錄

A部分:全球市場預測

第1章 簡介

第2章 法規形勢

  • 美國
  • 歐洲
  • 世界衛生組織(WHO)
  • 加拿大
  • 韓國
  • 中國
  • 印度
  • 日本
  • 墨西哥
  • 巴西
  • 阿根廷

第3章 主要市場趨勢

第4章 最近的生物相似藥的認證

第5章 全球主要企業

  • Amgen Inc. (The United States)
  • AXXO GmbH (Germany)
  • BIOCAD (Russia)
  • Biogen, Inc. (The United States)
  • Bioton S.A. (Poland)
  • C.H. Boehringer Sohn AG & Co., KG. (Germany)
  • Coherus Biosciences (The United States)
  • Creative BioMart (The United States)
  • Dong-A Socio Group (South Korea)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Eli Lilly and Company (The United States)
  • Genor Biopharma Co., Ltd. (China)
  • Hetero Drugs Limited (India)
  • Insud Pharma SL (Spain)
  • mAbxience SA (Spain)
  • Intas Pharmaceuticals Ltd. (India)
  • Kashiv Biosciences LLC (The United States)
  • LG Chem (South Korea)
  • Lupin Limited (India)
  • Mylan, Inc (The United States)
  • Nippon Kayaku Co., Ltd. (Japan)
  • Pfizer, Inc. (The United States)
  • Reliance Life Sciences Pvt. Ltd. (India)
  • Sandoz International GmbH (Germany)
  • Shanghai Henlius Biotech, Inc. (China)
  • STADA Arzneimittel AG (Germany)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Wockhardt Limited (India)

第6章 主要商務趨勢與產品趨勢

第7章 全球市場概要

  • 全球生物相似藥市場概要:各產品類型
  • 全球生物相似藥市場概要:各治療領域

B部分:地區市場預測

地區市場概要

第8章 歐洲

  • 歐洲的生物相似藥市場概要:各地區
  • 歐洲的生物相似藥市場概要:各產品類型
  • 歐洲的生物相似藥市場概要:各治療領域
  • 主要的市場企業
    • AXXO GmbH (Germany)
    • BIOCAD (Russia)
    • Bioton S.A. (Poland)
    • C.H. Boehringer Sohn AG & Co., KG. (Germany)
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • Fresenius Kabi AG (Germany)
    • Insud Pharma SL (Spain)
    • mAbxience SA (Spain)
    • Sandoz International GmbH (Germany)
    • STADA Arzneimittel AG (Germany)
  • 歐洲的生物相似藥市場各國分析
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 其他的歐洲

第9章 北美

  • 北美的生物相似藥市場概要:各地區
  • 北美的生物相似藥市場概要:各產品類型
  • 北美的生物相似藥市場概要:各治療領域
  • 主要的市場企業
    • Amgen Inc. (The United States)
    • Apotex, Inc. (Canada)
    • Biogen, Inc. (The United States)
    • Coherus BioSciences (The United States)
    • Creative Biomart, Inc. (The United States)
    • Eli Lilly and Company (The United States)
    • Kashiv Biosciences LLC (The United States)
    • Mylan, Inc (The United States)
    • Pfizer, Inc. (The United States)
    • Probiomed S.A. De C.V (Mexico)
  • 北美的生物相似藥市場各國分析
    • 美國
    • 加拿大
    • 墨西哥

第10章 亞太地區

  • 亞太地區的生物相似藥市場概要:各地區
  • 亞太地區的生物相似藥市場概要:各產品類型
  • 亞太地區的生物相似藥市場概要:各治療領域
  • 主要的市場企業
    • Celltrion, Inc. (South Korea)
    • Dong-A Socio Group (South Korea)
    • Dr. Reddy's Laboratories Ltd. (India)
    • Genor Biopharma Co., Ltd. (China)
    • Hetero Drugs Limited (India)
    • Intas Pharmaceuticals Ltd (India)
    • LG Chem (South Korea)
    • Lupin Limited (India)
    • Nippon Kayaku Co., Ltd. (Japan)
    • Reliance Life Sciences Pvt., Ltd. (India)
    • Samsung Biologics Co., Ltd. (South Korea)
    • Shanghai Henlius Biotech, Inc. (China)
    • Wockhardt Limited (India)
    • Zydus Cadila (India)
  • 亞太地區的生物相似藥市場各國分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他的亞太地區

第11章 其他地區

  • 其他地區的生物相似藥市場概要:各地區
  • 其他地區的生物相似藥市場概要:各產品類型
  • 其他地區的生物相似藥市場概要:各治療領域
  • 主要的市場企業
  • 其他地區的生物相似藥市場各國分析
    • 巴西
    • 以色列
    • 其他

C部分:產業指南

D部分:附錄

  • 1. 調查手法
  • 2. 回饋
目錄
Product Code: BT010

Report Synopsis

Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies' commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships. The solution to 'build versus buy' is no longer driven by the size, scale, and cost of a sales force leading to outdated product P&L's. However, a hybrid solution that a partial build plus skilled, experienced contractors plus CSO for sales reps will be the optimal solution. This hybrid model could allow for greater biosimilar uptake and more efficient uptake.

Global market for Biosimilars is dominated by Oncology, estimated at US$5.4 billion (38.6% share) in 2020, which is anticipated to post the slowest CAGR of 29% between 2020 and 2026 and reach a projected US$24.8 billion by 2026.

Research Findings & Coverage

  • Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas
  • The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally
  • mAbs - All the Rage in Biosimilars' New Wave
  • Patent Expirations of Major Biologics Leads Way for Biosimilars
  • Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
  • Availability of Biosimilar May Affect Biologic Drug Pricing
  • Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
  • Major companies profiled - 36
  • The industry guide includes the contact details for 155 companies

Product Outline

The report analyzes the market for the following key product types of Biosimilars:

  • Monoclonal Antibodies (mAB)
  • Erythropoietin (EPO)
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Insulin
  • Others (includes Interferons, Follitropins, Recombinant Proteins etc.)

Therapeutic areas of Biosimilars analyzed in this study comprise the following:

  • Oncology
  • Autoimmune Disorders
  • Blood Disorders
  • Growth Hormone Deficiency
  • Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)

Analysis Period, Units and Growth Rates

The report reviews, analyzes and projects the global Biosimilars market for the period 2017-2026 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2019 through 2026.

Geographic Coverage

  • North America (The United States, Canada and Mexico)
  • Europe (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)
  • Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
  • Rest of World (Brazil, Israel and Other Rest of World)

TABLE OF CONTENTS

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

  • 1.1 Product Outline
    • 1.1.1 Biosimilars Defined
    • 1.1.2 Backdrop
    • 1.1.3 The Biologics Price Competition and Innovation Act (BPCI Act)
      • 1.1.3.1 Data Exclusivity
    • 1.1.4 Steps Involved in Biosimilar Synthesis
    • 1.1.5 Key Regulatory Authorization Pathway - Synopsis
    • 1.1.6 Biosimilars Types
      • 1.1.6.1 Monoclonal Antibodies (mAB or moAB)
        • 1.1.6.1.1 Production Process
          • 1.1.6.1.1.1 Hybridoma Cell Production
        • 1.1.6.1.2 Therapeutic Applications
      • 1.1.6.2 Erythropoietin (EPO)
        • 1.1.6.2.1 Functions of EPO
        • 1.1.6.2.2 Mechanism of Action
        • 1.1.6.2.3 Synthesis and Regulation
        • 1.1.6.2.4 Uses in Medicine
      • 1.1.6.3 Granulocyte Colony-Stimulating Factor (G-CSF)
        • 1.1.6.3.1 Biological Function
        • 1.1.6.3.2 Genetics
        • 1.1.6.3.3 Use in Therapeutics
      • 1.1.6.4 Insulin
        • 1.1.6.4.1 Biosimilar Insulin
        • 1.1.6.4.2 The Complexity in Producing Biosimilar Insulin
        • 1.1.6.4.3 Biosimilar Insulins and the Regulatory Environment Surrounding Them
        • 1.1.6.4.4 The Market for Biosimilar Insulins
      • 1.1.6.5 Interferons
        • 1.1.6.5.1 Interferon Categorization
        • 1.1.6.5.2 Functions of Interferons
        • 1.1.6.5.3 Interferon Alfa
        • 1.1.6.5.4 Interferon Beta-1a
        • 1.1.6.5.5 Interferon Gamma
      • 1.1.6.6 Human Growth Hormone
        • 1.1.6.6.1 Recombinant Human Growth Hormone
        • 1.1.6.6.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars
      • 1.1.6.7 Other Biosimilars
    • 1.1.7 Biosimilars Therapeutic Areas
      • 1.1.7.1 Oncology
        • 1.1.7.1.1 Biosimilar G-CSF
      • 1.1.7.2 Autoimmune Diseases
      • 1.1.7.3 Blood Disorders
      • 1.1.7.4 Growth Hormone Deficiency (GHD)
        • 1.1.7.4.1 Growth Hormone Deficiency in Children
      • 1.1.7.5 Infectious Diseases
        • 1.1.7.5.1 Treatment of Infectious Diseases

2. REGULATORY LANDSCAPE

  • 2.1 The United States
    • 2.1.1 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
    • 2.1.2 Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product
    • 2.1.3 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
    • 2.1.4 FDA Issues New Regulatory Updates in 2020
  • 2.2 European
  • 2.3 The World Health Organization (WHO)
  • 2.4 Canada
  • 2.5 South Korea
  • 2.6 China
  • 2.7 India
  • 2.8 Japan
  • 2.9 Mexico
  • 2.10 Brazil
  • 2.11 Argentina

3. KEY MARKET TRENDS

  • 3.1 mAbs - All The Rage In Biosimilars' New Wave
    • 3.1.1 The Buildup to the Biosimilar Industry
    • 3.1.2 Biosimilars of mAbs Approved: A Sneak Preview
  • 3.2 Patent Expirations of Major Biologics Leads Way for Biosimilars
  • 3.3 Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
  • 3.4 Availability of Biosimilar May Affect Biologic Drug Pricing
  • 3.5 Asia-Pacific Witnessing a Boom of Biosimilars

4. RECENT BIOSIMILARS APPROVALS

5. KEY GLOBAL PLAYERS

  • Amgen Inc. (The United States)
  • AXXO GmbH (Germany)
  • BIOCAD (Russia)
  • Biogen, Inc. (The United States)
  • Bioton S.A. (Poland)
  • C.H. Boehringer Sohn AG & Co., KG. (Germany)
  • Coherus Biosciences (The United States)
  • Creative BioMart (The United States)
  • Dong-A Socio Group (South Korea)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Eli Lilly and Company (The United States)
  • Genor Biopharma Co., Ltd. (China)
  • Hetero Drugs Limited (India)
  • Insud Pharma SL (Spain)
  • mAbxience SA (Spain)
  • Intas Pharmaceuticals Ltd. (India)
  • Kashiv Biosciences LLC (The United States)
  • LG Chem (South Korea)
  • Lupin Limited (India)
  • Mylan, Inc (The United States)
  • Nippon Kayaku Co., Ltd. (Japan)
  • Pfizer, Inc. (The United States)
  • Reliance Life Sciences Pvt. Ltd. (India)
  • Sandoz International GmbH (Germany)
  • Shanghai Henlius Biotech, Inc. (China)
  • STADA Arzneimittel AG (Germany)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Wockhardt Limited (India)

6. KEY BUSINESS AND PRODUCT TRENDS

  • AbbVie Inc and Frontier Collaborate on Novel Therapies and E3 Degraders
  • Eli Lilly and UHG Collaborate on Bamlanivimab (LY-CoV555) Antibody Study
  • Merck Receives FDA Review Acceptance for KEYTRUDA® (pembrolizumab) Plus Chemotherapy
  • Samsung Bioepis and Biogen File U.S FDA Acceptance of SB11 Biosimilar
  • EMA Approves Roche's Xofluza® Biosimilar
  • Genor's New Drug Application for GB242 Infliximab Biosimilar is Under Review by NMPA
  • NeuClone Discloses it's Stelara® Biosimilar Candidate Clinical Trials
  • FDA Approval for Anti-IL-4Rα Monoclonal Antibody
  • Pfizer's NYVEPRIA™ Biosimilar Receives FDA Approval
  • Biocon Ltd Establishes Biosimilar Plant in India
  • Boehringer Acquires Northern Biologics, Inc
  • Biocon Ltd. and Mylan N.V Unveils Fulphila® Biosimilar
  • mAbxience Establishes New Biosimilar Antibody Plant in Argentina
  • CHMP Recommends RUXIENCE™ Biosimilar
  • FDA Approval for ABP 798, a Biosimilar Candidate to Rituxan®
  • Amgen Receives FDA Approval for its AVSOLA™ (Infliximab-axxq) Biosimilar Antibody
  • 3SBio, Inc and Verseau Agree on Monoclonal Antibody Development - VTX-0811
  • Boehringer Ingelheim Discloses GioTag Study Results
  • Dr. Reddy's Lab Unveils Versavo® Biosimilar
  • Allergan and Gedeon Receive FDA Approval for VRAYLAR® Drug Use
  • Samsung Bioepis Signs Biosimilars Development and Marketing Agreement with C-Bridge Capital
  • Biosimilar Association of Samsung Bioepis and 3SBio
  • Kashiv Pharma Renamed as KashivBioSciences Post Acquiring Adello Biologics
  • Intas Unveils New Pegylated G-CSF Biosimilar in Europe
  • Japanese Release of Trastuzumab and Agalsidase Beta Biosimilar
  • Epoetin Alfa and Pegfilgrastim Biosimilars Now Accessible In the US at Considerable Concession
  • Biosimilars of Insulin Glargine Introduced in South Korea and the UK
  • CNDA Accepted Review of Adalimumab Biosimilar
  • Filgrastim Biosimilar Application Submitted to the US FDA
  • European Commercial Release of Amgevita and Imraldi
  • MHLW of Japan Received Approval Application for Dual Darbepoetin Alfa Copy Biologics
  • Evaluation of Adalimumab Biosimilar SB5 by USFDA
  • Acceptance of Approval Application by CFDA for Adalimumab Biosimilar
  • Review Acceptance for MabionCD20 by EMA and Rituxan Expanded the Therapeutic Range
  • Dr Reddy's Introduces Hervycta, A Trastuzumab Biosimilar in India
  • Apotex Influence Canadian Biosimilar Market
  • Resubmission of Marketing Approval of Biosimilar Rituximab to FDA by Celltrion
  • Refusal of Trastuzumab and Rituximab Biosimilars Approval Applications by FDA
  • Rejection of Rituximab and Trastuzumab of Celltrion/Teva by FDA
  • Amgen and Allergan Authorize ABP 980 Biosimilar
  • OntruzantTrastuzumab Biosimilar Released in the UK
  • Commercialization of Trastuzumab Biosimilar in South Korea By Daewoong
  • Commercial Release of Adalimumab Biosimilar in India by Hetero
  • Production of Denosumab Biosimilar in Australia

7. GLOBAL MARKET OVERVIEW

  • 7.1 Global Biosimilars Market Overview by Product Type
    • 7.1.1 Global Biosimilars Product Types Market Overview by Geographic Region
      • 7.1.1.1 Monoclonal Antibodies
      • 7.1.1.2 Erythropoietin
      • 7.1.1.3 G-CSF
      • 7.1.1.4 Insulin
      • 7.1.1.5 Other Product Types
  • 7.2 Global Biosimilars Market Overview by Therapeutic Area
    • 7.2.1 Global Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 7.2.1.1 Oncology
      • 7.2.1.2 Autoimmune Disorders
      • 7.2.1.3 Blood Disorders
      • 7.2.1.4 Growth Hormone Deficiency
      • 7.2.1.5 Other Therapeutic Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

8. EUROPE

  • 8.1 European Biosimilars Market Overview by Geographic Region
  • 8.2 European Biosimilars Market Overview by Product Type
    • 8.2.1 European Biosimilars Product Types Market Overview by Geographic Region
      • 8.2.1.1 Monoclonal Antibodies
      • 8.2.1.2 Erythropoietin
      • 8.2.1.3 G-CSF
      • 8.2.1.4 Insulin
      • 8.2.1.5 Other Product Types
  • 8.3 European Biosimilars Market Overview by Therapeutic Area
    • 8.3.1 European Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 8.3.1.1 Oncology
      • 8.3.1.2 Autoimmune Disorders
      • 8.3.1.3 Blood Disorders
      • 8.3.1.4 Growth Hormone Deficiency
      • 8.3.1.5 Other Therapeutic Areas
  • 8.4 Major Market Players
    • AXXO GmbH (Germany)
    • BIOCAD (Russia)
    • Bioton S.A. (Poland)
    • C.H. Boehringer Sohn AG & Co., KG. (Germany)
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • Fresenius Kabi AG (Germany)
    • Insud Pharma SL (Spain)
    • mAbxience SA (Spain)
    • Sandoz International GmbH (Germany)
    • STADA Arzneimittel AG (Germany)
  • 8.5 Country-wise analysis of European Biosimilars Market
    • 8.5.1 Germany
      • 8.5.1.1 German Biosimilars Market Overview by Product Type
      • 8.5.1.2 German Biosimilars Market Overview by Therapeutic Area
    • 8.5.2 United Kingdom
      • 8.5.2.1 United Kingdom Biosimilars Market Overview by Product Type
      • 8.5.2.2 United Kingdom Biosimilars Market Overview by Therapeutic Area
    • 8.5.3 France
      • 8.5.3.1 French Biosimilars Market Overview by Product Type
      • 8.5.3.2 French Biosimilars Market Overview by Therapeutic Area
    • 8.5.4 Spain
      • 8.5.4.1 Spanish Biosimilars Market Overview by Product Type
      • 8.5.4.2 Spanish Biosimilars Market Overview by Therapeutic Area
    • 8.5.5 Italy
      • 8.5.5.1 Italian Biosimilars Market Overview by Product Type
      • 8.5.5.2 Italian Biosimilars Market Overview by Therapeutic Area
    • 8.5.6 Rest of Europe
      • 8.5.6.1 Rest of Europe Biosimilars Market Overview by Product Type
      • 8.5.6.2 Rest of Europe Biosimilars Market Overview by Therapeutic Area

9. NORTH AMERICA

  • 9.1 North American Biosimilars Market Overview by Geographic Region
  • 9.2 North American Biosimilars Market Overview by Product Type
    • 9.2.1 North American Biosimilars Product Types Market Overview by Geographic Region
      • 9.2.1.1 Monoclonal Antibodies
      • 9.2.1.2 Erythropoietin
      • 9.2.1.3 G-CSF
      • 9.2.1.4 Insulin
      • 9.2.1.5 Other Product Types
  • 9.3 North American Biosimilars Market Overview by Therapeutic Area
    • 9.3.1 North American Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 9.3.1.1 Oncology
      • 9.3.1.2 Autoimmune Disorders
      • 9.3.1.3 Blood Disorders
      • 9.3.1.4 Growth Hormone Deficiency
      • 9.3.1.5 Other Therapeutic Areas
  • 9.4 Major Market Players
    • Amgen Inc. (The United States)
    • Apotex, Inc. (Canada)
    • Biogen, Inc. (The United States)
    • Coherus BioSciences (The United States)
    • Creative Biomart, Inc. (The United States)
    • Eli Lilly and Company (The United States)
    • Kashiv Biosciences LLC (The United States)
    • Mylan, Inc (The United States)
    • Pfizer, Inc. (The United States)
    • Probiomed S.A. De C.V (Mexico)
  • 9.5 Country-wise Analysis of North American Biosimilars Market
    • 9.5.1 The United States
      • 9.5.1.1 United States Biosimilars Market Overview by Product Type
      • 9.5.1.2 United States Biosimilars Market Overview by Therapeutic Area
    • 9.5.2 Canada
      • 9.5.2.1 Canadian Biosimilars Market Overview by Product Type
      • 9.5.2.2 Canadian Biosimilars Market Overview by Therapeutic Area
    • 9.5.3 Mexico
      • 9.5.3.1 Mexican Biosimilars Market Overview by Product Type
      • 9.5.3.2 Mexican Biosimilars Market Overview by Therapeutic Area
  • 10. ASIA-PACIFIC
  • 10.1 Asia-Pacific Biosimilars Market Overview by Geographic Region
  • 10.2 Asia-Pacific Biosimilars Market Overview by Product Type
    • 10.2.1 Asia-Pacific Biosimilars Product Types Market Overview by Geographic Region
      • 10.2.1.1 Monoclonal Antibodies
      • 10.2.1.2 Erythropoietin
      • 10.2.1.3 G-CSF
      • 10.2.1.4 Insulin
      • 10.2.1.5 Other Product Types
  • 10.3 Asia-Pacific Biosimilars Market Overview by Therapeutic Area
    • 10.3.1 Asia-Pacific Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 10.3.1.1 Oncology
      • 10.3.1.2 Autoimmune Disorders
      • 10.3.1.3 Blood Disorders
      • 10.3.1.4 Growth Hormone Deficiency
      • 10.3.1.5 Other Therapeutic Areas
  • 10.4 Major Market Players
    • Celltrion, Inc. (South Korea)
    • Dong-A Socio Group (South Korea)
    • Dr. Reddy's Laboratories Ltd. (India)
    • Genor Biopharma Co., Ltd. (China)
    • Hetero Drugs Limited (India)
    • Intas Pharmaceuticals Ltd (India)
    • LG Chem (South Korea)
    • Lupin Limited (India)
    • Nippon Kayaku Co., Ltd. (Japan)
    • Reliance Life Sciences Pvt., Ltd. (India)
    • Samsung Biologics Co., Ltd. (South Korea)
    • Shanghai Henlius Biotech, Inc. (China)
    • Wockhardt Limited (India)
    • Zydus Cadila (India)
  • 10.5 Country-wise Analysis of Asia-Pacific Biosimilars Market
    • 10.5.1 China
      • 10.5.1.1 Chinese Biosimilars Market Overview by Product Type
      • 10.5.1.2 Chinese Biosimilars Market Overview by Therapeutic Area
    • 10.5.2 India
      • 10.5.2.1 Indian Biosimilars Market Overview by Product Type
      • 10.5.2.2 Indian Biosimilars Market Overview by Therapeutic Area
    • 10.5.3 Japan
      • 10.5.3.1 Japanese Biosimilars Market Overview by Product Type
      • 10.5.3.2 Japanese Biosimilars Market Overview by Therapeutic Area
    • 10.5.4 South Korea
      • 10.5.4.1 South Korean Biosimilars Market Overview by Product Type
      • 10.5.4.2 South Korean Biosimilars Market Overview by Therapeutic Area
    • 10.5.5 Rest of Asia-Pacific
      • 10.5.5.1 Rest of Asia-Pacific Biosimilars Market Overview by Product Type
      • 10.5.5.2 Rest of Asia-Pacific Biosimilars Market Overview by Therapeutic Area
  • 11. REST OF WORLD
  • 11.1 Rest of World Biosimilars Market Overview by Geographic Region
  • 11.2 Rest of World Biosimilars Market Overview by Product Type
    • 11.2.1 Rest of World Biosimilars Product Types Market Overview by Geographic Region
      • 11.2.1.1 Monoclonal Antibodies
      • 11.2.1.2 Erythropoietin
      • 11.2.1.3 G-CSF
      • 11.2.1.4 Insulin
      • 11.2.1.5 Other Product Types
  • 11.3 Rest of World Biosimilars Market Overview by Therapeutic Area
    • 11.3.1 Rest of World Biosimilars Therapeutic Area Market Overview by Geographic Region
      • 11.3.1.1 Oncology
      • 11.3.1.2 Autoimmune Disorders
      • 11.3.1.3 Blood Disorders
      • 11.3.1.4 Growth Hormone Deficiency
      • 11.3.1.5 Other Therapeutic Areas
  • 11.4 Major Market Players
  • 11.5 Country-wise Analysis of Rest of World Biosimilars Market
    • 11.5.1 Brazil
      • 11.5.1.1 Brazilian Biosimilars Market Overview by Product Type
      • 11.5.1.2 Brazilian Biosimilars Market Overview by Therapeutic Area
    • 11.5.2 Israel
      • 11.5.2.1 Israeli Biosimilars Market Overview by Product Type
      • 11.5.2.2 Israeli Biosimilars Market Overview by Therapeutic Area
    • 11.5.3 Other Countries
      • 11.5.3.1 Other Countries Biosimilars Market Overview by Product Type
      • 11.5.3.2 Other Countries Biosimilars Market Overview by Therapeutic Area

PART C: GUIDE TO THE INDUSTRY

  • 1. NORTH AMERICA
  • 2. EUROPE
  • 3. ASIA-PACIFIC
  • 4. REST OF WORLD

PART D: ANNEXURE

  • 1. RESEARCH METHODOLOGY
  • 2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

  • Chart 1: Global Biosimilars Market (2020 & 2026) by Geographic Region
  • Chart 2: Global Biosimilars Market (2020 & 2026) by Product Type
  • Chart 3: Global Biosimilars Market (2020 & 2026) by Therapeutic Areas
  • Chart 4: Global Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 5: Global Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 6: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 7: Global Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million
  • Chart 8: Glance at 2017, 2020 and 2026 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 9: Global Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 10: Glance at 2017, 2020 and 2026 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 11: Global Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 12: Glance at 2017, 2020 and 2026 Global Biosimilar G-CSF Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 13: Global Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 14: Glance at 2017, 2020 and 2026 Global Biosimilar Insulin Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 15: Global Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 16: Glance at 2017, 2020 and 2026 Global Other Biosimilar Products Types Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 17: Global Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 18: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 19: Global Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 20: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Oncology by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 21: Global Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 22: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 23: Global Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 24: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 25: Global Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 26: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Europe, North America, Asia-Pacific and Rest of World
  • Chart 27: Global Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in US$ Million
  • Chart 28: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

  • Chart 29: Global Biosimilars Market Analysis (2017-2026) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World in USD Million
  • Chart 30: Glance at 2017, 2020 and 2026 Global Biosimilars Market Share (%) by Geographic Region - Europe, North America, Asia-Pacific and Rest of World

REGIONAL MARKET OVERVIEW

EUROPE

  • Chart 31: European Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 32: European Biosimilars Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million
  • Chart 33: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 34: European Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 35: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 36: European Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in USD Million
  • Chart 37: Glance at 2017, 2020 and 2026 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 38: European Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 39: Glance at 2017, 2020 and 2026 European Biosimilar Erythropoietin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 40: European Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 41: Glance at 2017, 2020 and 2026 European Biosimilar G-CSF Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 42: European Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 43: Glance at 2017, 2020 and 2026 European Biosimilar Insulin Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 44: European Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 45: Glance at 2017, 2020 and 2026 European Other Biosimilar Products Types Market Share (%) by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 46: European Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 47: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 48: European Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 49: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Oncology by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 50: European Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 51: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 52: European Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 53: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 54: European Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 55: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe
  • Chart 56: European Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe in US$ Million
  • Chart 57: Glance at 2017, 2020 and 2026 European Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Germany, United Kingdom, France, Spain, Italy and Rest of Europe

Germany

  • Chart 58: German Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 59: German Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 60: Glance at 2017, 2020 and 2026 German Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 61: German Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 62: Glance at 2017, 2020 and 2026 German Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

United Kingdom

  • Chart 63: United Kingdom Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 64: United Kingdom Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 65: Glance at 2017, 2020 and 2026 United Kingdom Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 66: United Kingdom Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 67: Glance at 2017, 2020 and 2026 United Kingdom Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

France

  • Chart 68: French Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 69: French Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 70: Glance at 2017, 2020 and 2026 French Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 71: French Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 72: Glance at 2017, 2020 and 2026 French Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Spain

  • Chart 73: Spanish Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 74: Spanish Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 75: Glance at 2017, 2020 and 2026 Spanish Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 76: Spanish Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 77: Glance at 2017, 2020 and 2026 Spanish Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Italy

  • Chart 78: Italian Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 79: Italian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 80: Glance at 2017, 2020 and 2026 Italian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 81: Italian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 82: Glance at 2017, 2020 and 2026 Italian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Rest of Europe

  • Chart 83: Rest of Europe Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 84: Rest of Europe Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 85: Glance at 2017, 2020 and 2026 Rest of Europe Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 86: Rest of Europe Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 87: Glance at 2017, 2020 and 2026 Rest of Europe Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

NORTH AMERICA

  • Chart 88: North American Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 89: North American Biosimilars Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in USD Million
  • Chart 90: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 91: North American Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 92: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 93: North American Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in USD Million
  • Chart 94: Glance at 2017, 2020 and 2026 North American Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 95: North American Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 96: Glance at 2017, 2020 and 2026 North American Biosimilar Erythropoietin Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 97: North American Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 98: Glance at 2017, 2020 and 2026 North American Biosimilar G-CSF Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 99: North American Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 100: Glance at 2017, 2020 and 2026 North American Biosimilar Insulin Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 101: North American Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 102: Glance at 2017, 2020 and 2026 North American Other Biosimilar Products Types Market Share (%) by Geographic Region - United States, Canada and Mexico
  • Chart 103: North American Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 104: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 105: North American Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 106: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Oncology by Geographic Region - United States, Canada and Mexico
  • Chart 107: North American Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 108: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - United States, Canada and Mexico
  • Chart 109: North American Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 110: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Blood Disorders by Geographic Region - United States, Canada and Mexico
  • Chart 111: North American Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 112: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - United States, Canada and Mexico
  • Chart 113: North American Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico in US$ Million
  • Chart 114: Glance at 2017, 2020 and 2026 North American Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - United States, Canada and Mexico

The United States

  • Chart 115: United States Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 116: United States Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 117: Glance at 2017, 2020 and 2026 United States Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 118: United States Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 119: Glance at 2017, 2020 and 2026 United States Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Canada

  • Chart 120: Canadian Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 121: Canadian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 122: Glance at 2017, 2020 and 2026 Canadian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 123: Canadian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 124: Glance at 2017, 2020 and 2026 Canadian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Mexico

  • Chart 125: Mexican Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 126: Mexican Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 127: Glance at 2017, 2020 and 2026 Mexican Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 128: Mexican Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 129: Glance at 2017, 2020 and 2026 Mexican Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

ASIA-PACIFIC

  • Chart 130: Asia-Pacific Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 131: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million
  • Chart 132: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 133: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 134: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 135: Asia-Pacific Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in USD Million
  • Chart 136: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 137: Asia-Pacific Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 138: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Erythropoietin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 139: Asia-Pacific Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 140: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar G-CSF Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 141: Asia-Pacific Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 142: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilar Insulin Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 143: Asia-Pacific Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 144: Glance at 2017, 2020 and 2026 Asia-Pacific Other Biosimilar Products Types Market Share (%) by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 145: Asia-Pacific Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 146: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 147: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 148: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Oncology by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 149: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 150: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 151: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 152: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Blood Disorders by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 153: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 154: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific
  • Chart 155: Asia-Pacific Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific in US$ Million
  • Chart 156: Glance at 2017, 2020 and 2026 Asia-Pacific Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - China, India, Japan, South Korea and Rest of Asia-Pacific

China

  • Chart 157: Chinese Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 158: Chinese Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 159: Glance at 2017, 2020 and 2026 Chinese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 160: Chinese Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 161: Glance at 2017, 2020 and 2026 Chinese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

India

  • Chart 162: Indian Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 163: Indian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 164: Glance at 2017, 2020 and 2026 Indian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 165: Indian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 166: Glance at 2017, 2020 and 2026 Indian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Japan

  • Chart 167: Japanese Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 168: Japanese Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 169: Glance at 2017, 2020 and 2026 Japanese Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 170: Japanese Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 171: Glance at 2017, 2020 and 2026 Japanese Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

South Korea

  • Chart 172: South Korean Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 173: South Korean Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 174: Glance at 2017, 2020 and 2026 South Korean Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 175: South Korean Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 176: Glance at 2017, 2020 and 2026 South Korean Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Rest of Asia-Pacific

  • Chart 177: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 178: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 179: Glance at 2017, 2020 and 2026 Rest of Asia-Pacific Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 180: Rest of Asia-Pacific Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 181: Glance at 2017, 2020 and 2026 Rest of Asia-Pacific Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

REST OF WORLD

  • Chart 182: Rest of World Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 183: Rest of World Biosimilars Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in USD Million
  • Chart 184: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 185: Rest of World Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 186: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 187: Rest of World Biosimilar Monoclonal Antibodies Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in USD Million
  • Chart 188: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 189: Rest of World Biosimilar Erythropoietin Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 190: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Erythropoietin Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 191: Rest of World Biosimilar G-CSF Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 192: Glance at 2017, 2020 and 2026 Rest of World Biosimilar G-CSF Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 193: Rest of World Biosimilar Insulin Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 194: Glance at 2017, 2020 and 2026 Rest of World Biosimilar Insulin Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 195: Rest of World Other Biosimilar Product Types Market Analysis (2017-2026) by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 196: Glance at 2017, 2020 and 2026 Rest of World Other Biosimilar Products Types Market Share (%) by Geographic Region - Brazil, Israel and Other Countries
  • Chart 197: Rest of World Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 198: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other
  • Chart 199: Rest of World Biosimilars Market Analysis (2017-2026) in Oncology by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 200: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Oncology by Geographic Region - Brazil, Israel and Other Countries
  • Chart 201: Rest of World Biosimilars Market Analysis (2017-2026) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 202: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Autoimmune Disorders by Geographic Region - Brazil, Israel and Other Countries
  • Chart 203: Rest of World Biosimilars Market Analysis (2017-2026) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 204: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Blood Disorders by Geographic Region - Brazil, Israel and Other Countries
  • Chart 205: Rest of World Biosimilars Market Analysis (2017-2026) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 206: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Growth Hormone Deficiency by Geographic Region - Brazil, Israel and Other Countries
  • Chart 207: Rest of World Biosimilars Market Analysis (2017-2026) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries in US$ Million
  • Chart 208: Glance at 2017, 2020 and 2026 Rest of World Biosimilars Market Share (%) in Other Therapeutic Areas by Geographic Region - Brazil, Israel and Other Countries

Brazil

  • Chart 209: Brazilian Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 210: Brazilian Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 211: Glance at 2017, 2020 and 2026 Brazilian Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 212: Brazilian Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 213: Glance at 2017, 2020 and 2026 Brazilian Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Israel

  • Chart 214: Israeli Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 215: Israeli Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 216: Glance at 2017, 2020 and 2026 Israeli Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 217: Israeli Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 218: Glance at 2017, 2020 and 2026 Israeli Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Other Countries

  • Chart 219: Other Countries Biosimilars Market Analysis (2017-2026) in USD Million
  • Chart 220: Other Countries Biosimilars Market Analysis (2017-2026) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other in USD Million
  • Chart 221: Glance at 2017, 2020 and 2026 Other Countries Biosimilars Market Share (%) by Product Type - Monoclonal Antibodies, Erythropoietin, G-CSF, Insulin and Other
  • Chart 222: Other Countries Biosimilars Market Analysis (2017-2026) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other in USD Million
  • Chart 223: Glance at 2017, 2020 and 2026 Other Countries Biosimilars Market Share (%) by Therapeutic Area - Oncology, Autoimmune Disorders, Blood Disorders, Growth Hormone Deficiency and Other

Tables:

  • Table 1: Biosimilar Synonyms
  • Table 2: Comparison of Generics and Biosimilars
  • Table 3: List of the US and European Approved Biosimilars for Diabetes
  • Table 4: List of the US and European Approved Biosimilars for Oncology
  • Table 5: List of the US and European Approved Biosimilars for Autoimmune Disorders
  • Table 6: List of the US and European Approved Biosimilars for Blood Disorders
  • Table 7: List of the US and European Approved Biosimilars for Other Indications
  • Table 8: List of Leading Bioloigcs Containing mAbs, Year of Approval and Patent Expiry in Europe and the United States
  • Table 9: Global Biosimilar Approvals Since 2006: mAbs Occupy Major Share
  • Table 10: Biosimilars Pipeline by Company
  • Table 11: Biosimilars Approvals from 2018 to 2020